Nanobiotix (NASDAQ:NBTX) Stock Price Up 8.9% - Time to Buy?

Key Points

• Shares jumped about 8.9% intraday to roughly $33.62 (high of $34.18) on low volume—6,247 shares traded versus an average of 44,243—after a prior close of $30.87.
• Analysts are mixed but leaning positive with a consensus rating of "Moderate Buy" and a $20 consensus target; recent notes include TD Cowen reaffirming a buy and Guggenheim raising its target to $26, while Weiss Ratings remains a sell.
• Nanobiotix is a clinical‑stage biotech whose lead product, NBTXR3, is a CE‑marked radioenhancer; latest quarterly results showed an EPS loss of $0.23 on $3.42M revenue and analysts forecast about a -1.18 EPS for the year, with institutional investors owning roughly 38.8% of the stock.

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report)'s share price traded up 8.9% during mid-day trading on Wednesday . The company traded as high as $34.18 and last traded at $33.6150. 6,247 shares traded hands during mid-day trading, a decline of 86% from the average session volume of 44,243 shares. The stock had previously closed at $30.87.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. TD Cowen reaffirmed a "buy" rating on shares of Nanobiotix in a research note on Thursday, March 12th. Guggenheim increased their target price on shares of Nanobiotix from $8.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, February 6th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Nanobiotix in a report on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Nanobiotix currently has an average rating of "Moderate Buy" and a consensus price target of $20.00.

Nanobiotix Stock Up 12.1%

The firm has a fifty day simple moving average of $27.62 and a two-hundred day simple moving average of $23.12.

Nanobiotix (NASDAQ:NBTX - Get Free Report) last issued its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $3.42 million during the quarter. As a group, equities research analysts forecast that Nanobiotix S.A. - Sponsored ADR will post -1.18 earnings per share for the current year.

Hedge Funds Weigh In On Nanobiotix

A number of institutional investors have recently made changes to their positions in NBTX. Optiver Holding B.V. bought a new stake in shares of Nanobiotix during the 3rd quarter worth $101,000. Royal Bank of Canada increased its stake in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company's stock valued at $61,000 after acquiring an additional 2,500 shares during the last quarter. Marshall Wace LLP purchased a new stake in Nanobiotix during the fourth quarter valued at about $220,000. Finally, Millennium Management LLC purchased a new stake in Nanobiotix during the fourth quarter valued at about $390,000. Institutional investors own 38.81% of the company's stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company's lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.